Biohaven Pharmaceutical Holding Company Ltd. Common Shares (BHVN) News
Filter BHVN News Items
BHVN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest BHVN News From Around the Web
Below are the latest news stories about BIOHAVEN LTD that investors may wish to consider to help them evaluate BHVN as an investment opportunity.
Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual MeetingBiohaven Ltd. (NYSE: BHVN) announced today that it is presenting expanded EEG and safety data for BHV-7000 at the 2023 American Epilepsy Society (AES) Annual Meeting, taking place December 1-5, 2023, in Orlando, Florida. The presentations include results from the BHV-7000 Phase 1 EEG biomarker study and additional BHV-7000 safety and tolerability data from Phase 1 single ascending dose (SAD) / multiple ascending dose (MAD) studies. Additional posters showcase BHV-7000's preclinical data, finding |
Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Biohaven... |
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year. |
Biohaven Ltd (BHVN) Reports Q3 2023 Financial Results: Advances in Clinical Programs and Strong ...Key Developments Include Progress in Immunology and CNS Programs, Enhanced by Successful Public Offering |
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business DevelopmentsBiohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones. |
Biohaven Ltd. (BHVN) Is a Great Choice for 'Trend' Investors, Here's WhyIf you are looking for stocks that are well positioned to maintain their recent uptrend, Biohaven Ltd. (BHVN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
Are Medical Stocks Lagging Biohaven Ltd. (BHVN) This Year?Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year. |
Here's Why Momentum in Biohaven Ltd. (BHVN) Should Keep goingBiohaven Ltd. (BHVN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. |
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), announced the presentation of preclinical data demonstrating the ability of taldefgrobep alfa to significantly reduce fat mass while increasing lean mass in an obese mouse model. Separately, data supporting the correlation between change in waist circumference and change in total body weight among adults living with overweight and obesity treated with approved anti-obesity medications were reported. Both sets of data were presented on October 15, 2023 at |
Biohaven Independent Director Acquires 8.0% More StockThose following along with Biohaven Ltd. ( NYSE:BHVN ) will no doubt be intrigued by the recent purchase of shares by... |